EA201890671A1 - Препараты полипептида фактора viii - Google Patents

Препараты полипептида фактора viii

Info

Publication number
EA201890671A1
EA201890671A1 EA201890671A EA201890671A EA201890671A1 EA 201890671 A1 EA201890671 A1 EA 201890671A1 EA 201890671 A EA201890671 A EA 201890671A EA 201890671 A EA201890671 A EA 201890671A EA 201890671 A1 EA201890671 A1 EA 201890671A1
Authority
EA
Eurasian Patent Office
Prior art keywords
fviii
factor viii
polypeptide
drugs
polypeptide factor
Prior art date
Application number
EA201890671A
Other languages
English (en)
Russian (ru)
Inventor
Кевин Малони
Ахмад Абдул-Фаттах
Дэниел Гейдж
Original Assignee
Биовератив Терапьютикс Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=50771579&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EA201890671(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Биовератив Терапьютикс Инк. filed Critical Биовератив Терапьютикс Инк.
Publication of EA201890671A1 publication Critical patent/EA201890671A1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36—Blood coagulation or fibrinolysis factors
    • A61K38/37—Factors VIII
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C07K14/755—Factors VIII, e.g. factor VIII C (AHF), factor VIII Ag (VWF)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2833—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against MHC-molecules, e.g. HLA-molecules
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Toxicology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
EA201890671A 2013-03-15 2014-03-14 Препараты полипептида фактора viii EA201890671A1 (ru)

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
US201361800293P 2013-03-15 2013-03-15
US201361817085P 2013-04-29 2013-04-29
US201361829884P 2013-05-31 2013-05-31
US201361839477P 2013-06-26 2013-06-26
US201361863860P 2013-08-08 2013-08-08
US201361876927P 2013-09-12 2013-09-12
US201361879955P 2013-09-19 2013-09-19
US201361897742P 2013-10-30 2013-10-30

Publications (1)

Publication Number Publication Date
EA201890671A1 true EA201890671A1 (ru) 2019-01-31

Family

ID=50771579

Family Applications (2)

Application Number Title Priority Date Filing Date
EA201890671A EA201890671A1 (ru) 2013-03-15 2014-03-14 Препараты полипептида фактора viii
EA201591439A EA030357B1 (ru) 2013-03-15 2014-03-14 Препараты полипептида фактора viii

Family Applications After (1)

Application Number Title Priority Date Filing Date
EA201591439A EA030357B1 (ru) 2013-03-15 2014-03-14 Препараты полипептида фактора viii

Country Status (20)

Country Link
US (3) US9623088B2 (cg-RX-API-DMAC7.html)
EP (3) EP4122487A1 (cg-RX-API-DMAC7.html)
JP (5) JP6330026B2 (cg-RX-API-DMAC7.html)
AU (4) AU2014228506A1 (cg-RX-API-DMAC7.html)
CA (1) CA2899737A1 (cg-RX-API-DMAC7.html)
CL (1) CL2015002720A1 (cg-RX-API-DMAC7.html)
DK (1) DK2968477T3 (cg-RX-API-DMAC7.html)
EA (2) EA201890671A1 (cg-RX-API-DMAC7.html)
ES (2) ES2776195T3 (cg-RX-API-DMAC7.html)
HU (1) HUE047933T2 (cg-RX-API-DMAC7.html)
LT (1) LT2968477T (cg-RX-API-DMAC7.html)
PH (2) PH12015501801B1 (cg-RX-API-DMAC7.html)
PL (2) PL2968477T3 (cg-RX-API-DMAC7.html)
PT (2) PT2968477T (cg-RX-API-DMAC7.html)
RS (1) RS60003B1 (cg-RX-API-DMAC7.html)
SG (2) SG10201805207QA (cg-RX-API-DMAC7.html)
SI (1) SI2968477T1 (cg-RX-API-DMAC7.html)
TW (2) TWI629993B (cg-RX-API-DMAC7.html)
UY (1) UY35462A (cg-RX-API-DMAC7.html)
WO (1) WO2014144795A1 (cg-RX-API-DMAC7.html)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX353233B (es) * 2009-12-06 2018-01-08 Bioverativ Therapeutics Inc Polipéptidos híbridos y quiméricos del factor viii-fc, y métodos de uso de los mismos.
LT2968477T (lt) * 2013-03-15 2020-03-10 Bioverativ Therapeutics Inc. Faktoriaus viii polipeptido kompozicijos
EA037906B1 (ru) 2013-03-15 2021-06-04 Биовератив Терапьютикс Инк. Препараты полипептида фактора ix
CN106317226B (zh) 2016-08-19 2017-09-05 安源医药科技（上海）有限公司 用于构建融合蛋白的连接肽
CN106279437B (zh) * 2016-08-19 2017-10-31 安源医药科技（上海）有限公司 高糖基化人凝血因子viii融合蛋白及其制备方法与用途
IL266972B2 (en) 2016-12-02 2024-04-01 Bioverativ Therapeutics Inc Methods of treating hemophilic arthropathy using chimeric clotting factors
KR20190091292A (ko) 2016-12-02 2019-08-05 바이오버라티브 테라퓨틱스 인크. 응고 인자에 대한 면역 내성 유도 방법
JP7039308B2 (ja) * 2017-02-08 2022-03-22 三洋化成工業株式会社 細胞培養用担体
KR102780287B1 (ko) 2017-08-09 2025-03-14 바이오버라티브 테라퓨틱스 인크. 핵산 분자 및 이의 용도
JP7370974B2 (ja) 2017-11-07 2023-10-30 ラニ セラピューティクス， エルエルシー 嚥下可能薬物送達デバイスを使用する腸管組織への送達のための凝固因子調製物
CA3099049A1 (en) 2018-05-18 2019-11-21 Bioverativ Therapeutics Inc. Methods of treating hemophilia a
BR112021002017A2 (pt) 2018-08-09 2021-05-11 Bioverativ Therapeutics Inc. moléculas de ácido nucleico e usos das mesmas para terapia genética não viral
JP7672334B2 (ja) * 2018-10-23 2025-05-07 ザ・チルドレンズ・ホスピタル・オブ・フィラデルフィア 第ｖｉｉｉ因子機能を調節するための組成物および方法
US20220088085A1 (en) * 2019-02-28 2022-03-24 Public University Corporation Yokohama City University Composition for treating blood coagulation and/or complement disorders
CN114008069A (zh) 2019-04-17 2022-02-01 科迪亚克生物科学公司 外来体和aav的组合物
TW202115127A (zh) * 2019-06-19 2021-04-16 美商百歐維拉提夫治療公司 治療血友病及低骨質密度之方法及組成物
WO2023219379A1 (ko) * 2022-05-10 2023-11-16 주식회사 녹십자 혈장 단백질의 동결 건조를 위한 신규한 액상 제형물
CA3256911A1 (en) * 2022-05-10 2025-04-15 Green Cross Corporation NEW LIQUID FORMULATION FOR PLASMATIC PROTEINS

Family Cites Families (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4757006A (en) 1983-10-28 1988-07-12 Genetics Institute, Inc. Human factor VIII:C gene and recombinant methods for production
EP0154316B1 (en) 1984-03-06 1989-09-13 Takeda Chemical Industries, Ltd. Chemically modified lymphokine and production thereof
US4965199A (en) 1984-04-20 1990-10-23 Genentech, Inc. Preparation of functional human factor VIII in mammalian cells using methotrexate based selection
JPH0788399B2 (ja) 1985-04-12 1995-09-27 ジェネティックス・インスチチュ−ト・インコ−ポレ−テッド 新規プロコアギュラント蛋白質
KR910006424B1 (ko) 1985-08-21 1991-08-24 인코텍스 비.브이 편성브리프(brief) 제조방법
EP0253870B1 (en) 1986-01-03 1993-03-31 Genetics Institute, Inc. Method for producing factor viii:c-type proteins
US5595886A (en) 1986-01-27 1997-01-21 Chiron Corporation Protein complexes having Factor VIII:C activity and production thereof
US5610278A (en) 1986-06-24 1997-03-11 Novo Nordisk A/S Process for producing a coagulation active complex of factor VIII fragments
US4912040A (en) 1986-11-14 1990-03-27 Genetics Institute, Inc. Eucaryotic expression system
CA1331157C (en) 1987-04-06 1994-08-02 Randal J. Kaufman Method for producing factor viii:c-type proteins
US6060447A (en) 1987-05-19 2000-05-09 Chiron Corporation Protein complexes having Factor VIII:C activity and production thereof
US6346513B1 (en) 1987-06-12 2002-02-12 Baxter Trading Gmbh Proteins with factor VIII activity: process for their preparation using genetically-engineered cells and pharmaceutical compositions containing them
IL86693A (en) 1987-06-12 1994-06-24 Stichting Centraal Lab Proteins with factor VIII activity, process for their preparation using genetically engineered cells and pharmaceutical compositions containing them
DE3720246A1 (de) 1987-06-19 1988-12-29 Behringwerke Ag Faktor viii:c-aehnliches molekuel mit koagulationsaktivitaet
FR2619314B1 (fr) 1987-08-11 1990-06-15 Transgene Sa Analogue du facteur viii, procede de preparation et composition pharmaceutique le contenant
US4994371A (en) 1987-08-28 1991-02-19 Davie Earl W DNA preparation of Christmas factor and use of DNA sequences
US5004803A (en) 1988-11-14 1991-04-02 Genetics Institute, Inc. Production of procoagulant proteins
WO1990006952A1 (fr) 1988-12-22 1990-06-28 Kirin-Amgen, Inc. Facteur de stimulation de colonies de granulocytes modifies chimiquement
DE69029799T2 (de) 1989-02-21 1997-05-28 Washington University, St. Louis, Mo. Modifizierte formen von fortpflanzungshormonen
SE465222C5 (sv) 1989-12-15 1998-02-10 Pharmacia & Upjohn Ab Ett rekombinant, humant faktor VIII-derivat och förfarande för dess framställning
US6552170B1 (en) 1990-04-06 2003-04-22 Amgen Inc. PEGylation reagents and compounds formed therewith
SG89295A1 (en) 1991-03-15 2002-06-18 Amgen Inc Pegylation of polypeptides
FR2686899B1 (fr) 1992-01-31 1995-09-01 Rhone Poulenc Rorer Sa Nouveaux polypeptides biologiquement actifs, leur preparation et compositions pharmaceutiques les contenant.
US5859204A (en) 1992-04-07 1999-01-12 Emory University Modified factor VIII
US6376463B1 (en) 1992-04-07 2002-04-23 Emory University Modified factor VIII
US5364771A (en) 1992-04-07 1994-11-15 Emory University Hybrid human/porcine factor VIII
NZ256921A (en) * 1992-10-02 1996-05-28 Pharmacia Ab Formulations of coagulation factor viii and a non-ionic surfactant and their preparation
US5563045A (en) 1992-11-13 1996-10-08 Genetics Institute, Inc. Chimeric procoagulant proteins
SE504074C2 (sv) 1993-07-05 1996-11-04 Pharmacia Ab Proteinberedning för subkutan, intramuskulär eller intradermal administrering
IL113010A0 (en) * 1994-03-31 1995-10-31 Pharmacia Ab Pharmaceutical formulation comprising factor VIII or factor ix with an activity of at least 200 IU/ml and an enhancer for improved subcutaneous intramuscular or intradermal administration
SE9503380D0 (sv) 1995-09-29 1995-09-29 Pharmacia Ab Protein derivatives
US6458563B1 (en) 1996-06-26 2002-10-01 Emory University Modified factor VIII
US5763401A (en) 1996-07-12 1998-06-09 Bayer Corporation Stabilized albumin-free recombinant factor VIII preparation having a low sugar content
CA2225189C (en) 1997-03-06 2010-05-25 Queen's University At Kingston Canine factor viii gene, protein and methods of use
US6200560B1 (en) 1998-10-20 2001-03-13 Avigen, Inc. Adeno-associated virus vectors for expression of factor VIII by target cells
ATE365052T1 (de) * 1999-02-22 2007-07-15 Univ Connecticut Neue albuminfreie faktor viii formulierungen
US7091321B2 (en) 2000-02-11 2006-08-15 Emd Lexigen Research Center Corp. Enhancing the circulating half-life of antibody-based fusion proteins
EP2261250B1 (en) 2001-12-21 2015-07-01 Human Genome Sciences, Inc. GCSF-Albumin fusion proteins
GB0207092D0 (en) 2002-03-26 2002-05-08 Sod Conseils Rech Applic Stable pharmaceutical composition containing factor VIII
US7041635B2 (en) 2003-01-28 2006-05-09 In2Gen Co., Ltd. Factor VIII polypeptide
AU2004239244C1 (en) 2003-05-06 2015-04-23 Bioverativ Therapeutics Inc. Clotting factor-Fc chimeric proteins to treat hemophilia
US7348004B2 (en) 2003-05-06 2008-03-25 Syntonix Pharmaceuticals, Inc. Immunoglobulin chimeric monomer-dimer hybrids
TWI353991B (en) 2003-05-06 2011-12-11 Syntonix Pharmaceuticals Inc Immunoglobulin chimeric monomer-dimer hybrids
US7211559B2 (en) 2003-10-31 2007-05-01 University Of Maryland, Baltimore Factor VIII compositions and methods
AU2004298789A1 (en) 2003-12-19 2005-06-30 Novo Nordisk Health Care Ag Stabilised compositions of factor VII polypeptides
NZ555032A (en) 2004-11-12 2010-02-26 Bayer Healthcare Llc Site-directed modification of FVIII
US8367805B2 (en) 2004-11-12 2013-02-05 Xencor, Inc. Fc variants with altered binding to FcRn
WO2007092772A2 (en) 2006-02-03 2007-08-16 Medimmune, Inc. Protein formulations
US8048848B2 (en) 2006-02-03 2011-11-01 Prolor Biotech Ltd. Long-acting interferons and derivatives thereof and methods thereof
KR101542752B1 (ko) 2006-12-22 2015-08-10 체에스엘 베링 게엠베하 연장된 생체내 반감기를 갖는 변형된 응고 인자
EA021222B8 (ru) 2007-06-21 2015-11-30 ИксЭль-ПРОТЕИН ГМБХ Биологически активные белки, имеющие повышенную стабильность in vivo и/или in vitro
US8239182B2 (en) 2007-12-04 2012-08-07 Spansion Llc Data transmission system-on-chip memory model based validation
EP2242505A4 (en) 2008-01-08 2012-03-07 Biogenerix Ag GLYCOCONJUGATION OF POLYPEPTIDES USING OLIGOSACCHARYLTRANSFERASES
CN102482340B (zh) 2009-04-06 2015-05-13 诺沃—诺迪斯克有限公司 因子viii蛋白向血小板的靶向递送
MX353233B (es) * 2009-12-06 2018-01-08 Bioverativ Therapeutics Inc Polipéptidos híbridos y quiméricos del factor viii-fc, y métodos de uso de los mismos.
JP2014522838A (ja) * 2011-07-08 2014-09-08 バイオジェン アイデック ヘモフィリア インコーポレイテッド 第ｖｉｉｉ因子キメラおよびハイブリッドポリペプチドならびにその使用法
WO2013057219A1 (en) * 2011-10-18 2013-04-25 Csl Behring Gmbh Method for improving the stability of purified factor viii after reconstitution
JP2015527350A (ja) * 2012-08-13 2015-09-17 ノヴォ ノルディスク アー／エス 第ｖｉｉｉ因子の液体製剤
WO2014070953A1 (en) * 2012-10-30 2014-05-08 Biogen Idec Ma Inc. Methods of Using FVIII Polypeptide
LT2968477T (lt) 2013-03-15 2020-03-10 Bioverativ Therapeutics Inc. Faktoriaus viii polipeptido kompozicijos

Also Published As

Publication number Publication date
JP7240457B2 (ja) 2023-03-15
EP3666283B1 (en) 2022-06-08
SG10201805207QA (en) 2018-07-30
JP2020186268A (ja) 2020-11-19
CA2899737A1 (en) 2014-09-18
JP7700164B2 (ja) 2025-06-30
JP2023060146A (ja) 2023-04-27
PT2968477T (pt) 2020-03-11
TWI690325B (zh) 2020-04-11
UY35462A (es) 2014-10-31
JP2016516722A (ja) 2016-06-09
ES2776195T3 (es) 2020-07-29
AU2025204069A1 (en) 2025-06-26
TW201842930A (zh) 2018-12-16
TWI629993B (zh) 2018-07-21
DK2968477T3 (da) 2020-03-09
JP2018123161A (ja) 2018-08-09
CL2015002720A1 (es) 2016-11-04
ES2926798T3 (es) 2022-10-28
PL3666283T3 (pl) 2022-10-03
PH12015501801A1 (en) 2015-11-09
RS60003B1 (sr) 2020-04-30
US20210069300A1 (en) 2021-03-11
EP4122487A1 (en) 2023-01-25
AU2014228506A1 (en) 2015-08-13
EA201591439A1 (ru) 2016-03-31
HK1220617A1 (en) 2017-05-12
AU2019202656A1 (en) 2019-05-09
AU2019202656B2 (en) 2021-09-02
SI2968477T1 (sl) 2020-04-30
US20170281734A1 (en) 2017-10-05
SG11201505924TA (en) 2015-09-29
LT2968477T (lt) 2020-03-10
JP6330026B2 (ja) 2018-05-23
EP3666283A1 (en) 2020-06-17
WO2014144795A1 (en) 2014-09-18
PL2968477T3 (pl) 2020-06-15
US20140308280A1 (en) 2014-10-16
JP6934994B2 (ja) 2021-09-15
AU2021277601B2 (en) 2025-03-06
EP2968477B1 (en) 2019-12-04
US12403183B2 (en) 2025-09-02
JP2021181491A (ja) 2021-11-25
PT3666283T (pt) 2022-09-13
AU2021277601A1 (en) 2021-12-23
EP2968477A1 (en) 2016-01-20
TW201501722A (zh) 2015-01-16
HUE047933T2 (hu) 2020-05-28
US10786554B2 (en) 2020-09-29
US9623088B2 (en) 2017-04-18
PH12015501801B1 (en) 2019-11-20
PH12019502452A1 (en) 2021-02-08
EA030357B1 (ru) 2018-07-31

Similar Documents

Publication Publication Date Title
EA201591439A1 (ru) Препараты полипептида фактора viii
EA202090919A1 (ru) Липидные наночастицы для доставки модифицированной рнк, кодирующей полипептид vegf-a
MX2019003716A (es) Formulaciones farmaceuticas de anticuerpos tnf-alfa.
MX2018012166A (es) Dosificacion oral de compuestos peptido similar al glaucon-1 (glp-1).
MX382917B (es) Formulaciones de proteínas líquidas que contienen líquidos iónicos.
EA202091342A2 (ru) Слитые белки интерлейкин-2/рецептор интерлейкина-2 альфа и способы применения
EA201991029A1 (ru) Ингибиторы magl
EA201690667A1 (ru) Композиции, содержащие антитело к pdl1
MX2015014017A (es) Variante de la region fc.
EA201690159A1 (ru) Способы и композиции для лечения рака
EA201591752A1 (ru) Дипептидные и трипептидные эпоксикетонные ингибиторы протеазы
EA201590162A1 (ru) МУТАНТНЫЕ ФРАГМЕНТЫ OspA И СВЯЗАННЫЕ С НИМИ СПОСОБЫ И ПРИМЕНЕНИЕ
UY35306A (es) Formulaciones farmacéuticas estabilizadas de análogos de insulina y/o derivados de insulina.
EP3871726A4 (en) NITRIC OXIDE DELIVERY DEVICE
EA201501054A1 (ru) Лечение миопатий и нейродегенеративных заболеваний, связанных с агрегацией белков, путём парентерального введения трегалозы
WO2015020913A3 (en) Influenza hemagglutinin proteins and methods of thereof
EA201591421A1 (ru) Препараты полипептида фактора ix
TN2014000498A1 (en) Pharmaceutical formulation
EA201491513A1 (ru) Рекомбинантные штаммы escherichia coli
EA201700019A1 (ru) Высокочистый оритаванцин и способ его получения
EP2991681C0 (en) TOPICAL COMPOSITION AND VEHICLE FOR THE ADMINISTRATION OF PHARMACEUTICAL OR COSMETIC ACTIVE INGREDIENTS
MX2019012506A (es) Formulaciones estables de proteinas de dominio andamio a base de fibronectina que se unen a miostatina.
PH12016500738A1 (en) Formulation for gonadotropins
EA201690826A1 (ru) Рекомбинантные гликопротеиды и их применения
EA201591832A1 (ru) Коэкспрессия фактора viii и фактора фон виллебранда